Lonza has reached a major milestone in its multiproduct partnership with Takeda Pharmaceutical Co. Takeda was granted marketing authorization by the European Commission for ALUNBRIG (brigatinib) as a ...
TxCell and Lonza entered into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.
Today, CRISPR/Cas9 has emerged as the genome editing method of choice in research and biotechnology. Compared to other gene editing technologies, it is simpler to re-engineer, easier to use, and can target multiple sites.
Lonza Pharma & Biotech announced the investment in a new phase of development at their Portsmouth (New Hampshire, USA) site. The expansion will include mid-scale mammalian capacity and the addition of new cell-therapy suites.